0001159036-26-000068
SEC filingQ1 2026 delivered exceptional financial performance with revenue up 42% to $376.7M, fueled by strong partner demand driving higher gross profit and operating income, alongside robust cash generation from operations despite increased capital investments.
Halozyme Therapeutics reported strong Q1 2026 results, with revenue reaching $376.7 million, a 42.2% increase from $264.9 million in the prior year quarter. This growth reflects robust demand from ENHANZE drug delivery partnerships and bulk rHuPH20 sales to collaborators, enabling subcutaneous administration of high-volume biologics like monoclonal antibodies. Gross profit expanded 37.4% to $297.5 million, delivering a 79.0% gross margin. The margin resilience stems from the scalability of our recombinant human hyaluronidase (rHuPH20) technology, which temporarily reduces tissue barriers for improved drug delivery, even as cost of sales rose primarily due to increased bulk rHuPH20 volumes.
Operating income climbed 30.4% to $184.5 million, achieving a 49.0% operating margin. This performance highlights effective cost management and the high-margin nature of royalty and product revenues, providing leverage as the company scales. Net income followed suit, rising 27.1% to $150.0 million, with diluted EPS advancing 31.2% to $1.22 from $0.93. These gains position Halozyme to deliver shareholder value through its enabling platform that enhances partner therapies' commercial viability.
Looking forward, Halozyme expects proprietary product sales growth through continued market share gains in testosterone replacement therapy, bolstering XYOSTED and related offerings. The company's financial strength enables investment in platform expansion and potential future transactions, maintaining flexibility in a dynamic biotech landscape.